Cargando…
Quantile regression to characterize solanezumab effects in Alzheimer's disease trials
INTRODUCTION: In two solanezumab trials for mild-to-moderate Alzheimer's disease (AD) dementia, 27% of patients had biomarker confirmation of amyloid status. Of these, approximately 25% of mild patients and approximately 10% of moderate patients were amyloid negative and, as a group, did not ex...
| Autores principales: | , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier
2016
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5651345/ https://www.ncbi.nlm.nih.gov/pubmed/29067306 http://dx.doi.org/10.1016/j.trci.2016.07.005 |